The largest study of ectopic Cushing syndrome maps who dies, and why

Ectopic Cushing syndrome is what happens when a tumour outside the pituitary — often in the lung, pancreas, or elsewhere — pumps out the hormone ACTH, driving cortisol to dangerous levels. It is rare, severe, and badly characterised, because no single centre sees enough cases to study it well. A retrospective cohort study published on 3 November in The Lancet Diabetes & Endocrinology pooled cases across continents to fix that [s1].

What the study did

Forty-nine high-volume endocrine referral centres across Asia, Europe, North America, South America, and New Zealand identified consecutive eligible patients with a clinical diagnosis of ectopic Cushing syndrome, confirmed by expert adjudication at the treating institution [s1]. Data collection ran between 31 May 2024 and 22 April 2025. The primary outcome was Cushing syndrome-related mortality, adjudicated by investigators; secondary outcomes were overall mortality and the incidence of complications, analysed with landmark methods that separate early events (within six months of diagnosis) from late ones [s1].

Two cautions frame everything below. This is retrospective and drawn from high-volume referral centres, so the sickest or most complex cases may be over-represented, and the diagnosis rested on local expert judgment rather than a single uniform biochemical rule — the condition is notoriously hard to pin down even with the standard diagnostic work-up [s2].

The numbers

The cohort included 1463 patients, with a median age of 51 years (IQR 37–64; range 3–87) [s1]. There were 824 women (56.3%) and 639 men (43.7%), and 1021 (69.8%) were of White race [s1]. More than half — 836 patients (57.1%) — had metastatic disease at the tumour source [s1].

The illness was biochemically severe. Severe hypercortisolism was present in 1204 of 1321 patients (91.1%) and hypokalaemia — low blood potassium, a hallmark of cortisol excess — in 1111 of 1399 (79.4%) [s1]. Over a median follow-up of 57 months (IQR 19–124), Cushing syndrome-related death occurred in 196 patients (13.4%), and 626 (42.8%) died from any cause [s1].

Complications were common and mostly a consequence of cortisol's effects. Infection occurred in 464 patients (31.7%), venous thromboembolism in 124 (8.5%), cardiovascular events in 93 (6.4%), and cerebrovascular events in 37 (2.5%) [s1].

The age range alone — from 3 to 87 years — signals how varied the underlying tumours are, since ectopic ACTH can come from aggressive cancers and from slow-growing neuroendocrine tumours alike [s1]. That the majority, 836 of 1463, had metastatic disease at the source helps explain why overall mortality (42.8%) so far outstrips the Cushing-specific figure (13.4%): for many patients the cancer, not the cortisol, is the ultimate threat [s1]. The landmark analysis is designed to hold those timelines apart, separating what happens in the first six months from what follows, so that early control is not credited with preventing deaths that occurred before remission could matter [s1].

The finding that matters for care

The actionable result is about timing. Achieving complete biochemical remission within six months of diagnosis was independently associated with a lower risk of late complications — an adjusted hazard ratio of 0.55 (95% CI 0.38–0.80) — and of Cushing syndrome-related mortality, 0.49 (0.27 to 0.89) [s1]. Notably, there was no association with non-Cushing-related mortality [s1].

That last detail is what makes the signal credible. If early remission were just a marker of healthier patients, it would predict fewer deaths of every kind. Instead it tracks only the deaths cortisol excess drives, which is what you would expect if controlling the hypercortisolism itself changes the outcome. In an observational study this is association, not proof — but it is the pattern a genuine treatment effect would leave.

Why speed is plausible as the lever

Cortisol at these levels is directly toxic: it suppresses immunity, promotes clotting, and destabilises the heart and vasculature, which is why infection and thromboembolism dominate the complication list [s1]. Shutting that down quickly, whether by removing the tumour or by controlling the hormone medically, plausibly interrupts the cascade before it does lasting damage. Diagnosis is the bottleneck, because ectopic sources can be small and hard to localise even with a thorough endocrine work-up [s2].

What to watch

This is the largest and most geographically broad description of ectopic Cushing syndrome to date, and its value is as a map: who presents how, what goes wrong, and how outcomes split by whether hypercortisolism is brought under control early [s1]. What it cannot settle is which treatment sequence gets patients to remission fastest. That is the question a prospective study, built on this scaffolding, would need to answer.

This article is informational and does not constitute medical advice.